<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3302">
  <stage>Registered</stage>
  <submitdate>19/09/2011</submitdate>
  <approvaldate>19/09/2011</approvaldate>
  <nctid>NCT01438229</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy Study of Renal Artery Ablation in Resistant Hypertension Patients</studytitle>
    <scientifictitle>Ablation-induced Renal Sympathetic Denervation Trial</scientifictitle>
    <utrn />
    <trialacronym>EnligHTN-I</trialacronym>
    <secondaryid>Arsenal</secondaryid>
    <secondaryid>CI-10-045-ID-HT</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypertension</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - St. Jude Medical renal artery ablation system: RF ablation generator (IBI 1500T11.5) and Renal artery ablation catheter (DS3D001, DS3D002)

Experimental: renal artery ablation - Catheter-based RF ablation in renal artery


Treatment: devices: St. Jude Medical renal artery ablation system: RF ablation generator (IBI 1500T11.5) and Renal artery ablation catheter (DS3D001, DS3D002)
Catheter-based RF ablation in renal artery

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Adverse Events - All device or procedure related adverse events</outcome>
      <timepoint>24 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Office Systolic Blood Pressure Change</outcome>
      <timepoint>Baseline to 6 months</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Office systolic blood pressure that remains =160 mmHg (=150 mmHg for patient with type
             2 diabetes) despite the stable use of =3 antihypertensive medications concurrently at
             maximally tolerated doses, of which one is a diuretic, for a minimum of 14 days prior
             to enrollment

          -  Age =18 and =80 years old

          -  Able and willing to provide written informed consent to participate in the study

          -  Able and willing to comply with the required follow-up schedule</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior renal artery intervention (balloon angioplasty or stenting)

          -  Evidence of renal artery atherosclerosis (defined as a stenotic severity of &gt;30%) in
             either renal artery

          -  Multiple main renal arteries in either kidney

          -  Main renal arteries &lt;4 mm in diameter or &lt;20 mm in length

          -  eGFR of &lt;45 mL/min per 1.73 m2 using the MDRD formula

          -  Type 1 diabetes

          -  Renovascular hypertension or hypertension secondary to other renal disorders
             (glomerulonephritis, polycystic kidney disease, end-stage renal failure)

          -  Others</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>47</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,VIC</recruitmentstate>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Flinders Medical Centre - Adelaide</hospital>
    <hospital>Monash Medical Centre - Melbourne</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>5042 - Adelaide</postcode>
    <postcode>3168 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>St. Jude Medical</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a prospective, multicenter, feasibility study on the safety and efficacy of renal
      denervation in patients with resistant hypertension.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01438229</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Vasilias Papademetriou, MD</name>
      <address>First Cardioligy Clinic, Hippokration Hospital, University of Athens, Greece</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>